invIOs GmbH

invIOs raises €8.2 million in a Series A to finance pipeline progress in immuno-oncology

invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma

invIOs to attend JP Morgan Week in San Francisco in January

invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma

invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding

invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors

invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023

invIOs to present at Biotech Showcase

invIOs GmbH: APEIRON Respiratory Therapies announces positive results from Phase I trial of inhaled APN01

invIOs präsentiert auf anstehenden Konferenzen

invIOs startet mit einzigartiger Zelltherapie-Plattform und klinischer Immunonkologie-Pipeline